)
Werewolf Therapeutics (HOWL) investor relations material
Werewolf Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Initiated a process to explore strategic alternatives, including sale, merger, asset sale, or partnerships, to maximize shareholder value.
Engaged Piper Sandler & Co. as exclusive financial advisor for the strategic review.
Focused on advancing conditionally activated therapeutics for cancer and immune-mediated conditions.
Financial highlights
Cash and cash equivalents were $57.1 million as of December 31, 2025, down from $65.7 million at September 30, 2025.
Research and development expenses were $6.9 million for Q4 2025 (down from $15.7 million in Q4 2024) and $44.8 million for FY 2025 (down from $56.4 million in FY 2024).
General and administrative expenses were $2.5 million for Q4 2025 (down from $4.6 million in Q4 2024) and $15.8 million for FY 2025 (down from $19.0 million in FY 2024).
Net loss was $8.4 million for Q4 2025 (improved from $20.4 million in Q4 2024) and $60.8 million for FY 2025 (improved from $70.5 million in FY 2024).
Cash runway expected to fund operations into Q4 2026.
Outlook and guidance
No defined timeline for the strategic review process; outcomes and timing remain uncertain.
Cash position projected to support operations into the fourth quarter of 2026.
- Durable responses and strong safety support expansion at 18mg in refractory solid tumors.HOWL
Study Update31 Jan 2026 - INDUKINE cytokine prodrugs deliver durable responses with favorable safety in advanced cancers.HOWL
7th Annual Evercore ISI HealthCONx Healthcare Conference11 Jan 2026 - WTX-124 demonstrates durable responses in tough cancers, with expansion and registration plans underway.HOWL
Leerink’s Global Healthcare Conference 202526 Dec 2025 - WTX-124 and WTX-330 show strong early efficacy and safety, with pivotal data expected in late 2024.HOWL
24th Annual Needham Virtual Healthcare Conference23 Dec 2025 - Shelf registration allows up to $150M in offerings, with $12.5M at-the-market via Leerink Partners.HOWL
Registration Filing16 Dec 2025 - Virtual meeting to elect directors and ratify auditor, with robust governance and compensation policies.HOWL
Proxy Filing2 Dec 2025 - Key votes include director elections and auditor ratification at the June 2025 virtual meeting.HOWL
Proxy Filing2 Dec 2025 - WTX-124 advances with strong safety, efficacy, and key data readouts expected in Q4.HOWL
BofA Securities 2025 Healthcare Conference24 Nov 2025 - Advancing cytokine therapies with robust clinical data, pipeline growth, and solid cash runway.HOWL
The Citizens JMP Life Sciences Conference 202521 Nov 2025
Next Werewolf Therapeutics earnings date
Next Werewolf Therapeutics earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
Frequently asked questions
Explore our global coverage
)
)